[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hidradenitis-suppurativa-acne-inversa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hidradenitis-suppurativa-acne-inversa":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,69,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100642252","global-healthcare-study-on-hidradenitis-suppurativa-100642252",false,"NCT07659769","Global Healthcare Study on Hidradenitis Suppurativa","GHSHS","Inclusion Criteria:\n\n* Signed General Consent Form, or equivalent document\n* Confirmed diagnosis of Hidradenitis Suppurativa\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Datasets with ambiguous or unclear diagnosis.","ALL","14 Years",{"count":19,"type":20},9600,"ESTIMATED","5 Years","OBSERVATIONAL","The Global Healthcare Study on Hidradenitis Suppurativa (GHSHS) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.",[25,26],"Hidradenitis Suppurativa (HS)","Hidradenitis Suppurativa (Acne Inversa)",[28,14,29],"Dermastudy","GHRSD","RECRUITING","2026-06-15",{"date":33,"type":34},"2026-06-22","ACTUAL",{"date":36,"type":34},"2025-01-01",{"date":38,"type":20},"2029-12-31",{"name":40,"class":41},"Julia Tatjana Maul","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":42},"100613014","phase-4-comparison-of-the-clinical-efficacy-and-safety-of-topical-and-subcutaneous-injection-of-secukinumab-in-hs-100613014","NCT07261072","Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS","Comparison of the Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS: A Prospective Exploratory Trial","Inclusion Criteria:\n\n1. Meet international diagnostic criteria for hidradenitis suppurativa\n2. Aged ≥ 18 years\n3. Disease duration ≥ 6 months and resistance to conventional therapy (no significant improvement for ≥ 3 months)\n4. Lesions were confined to a single anatomical area\n5. Voluntarily signed the informed consent form and was able to cooperate in all visits and examinations.\n\nExclusion Criteria:\n\n1. Hypersensitivity to any component of secukinumab injection\n2. With severe vital organ failure\n3. With active infection or malignancy (malignancy within the past 5 years, except for basal or squamous cell carcinoma of the skin and cured)\n4. Treatment with biologics, immunosuppressants, or systemic corticosteroids within the last 3 months\n5. Pregnant, nursing, or planning conception during the study\n6. Mental disorders or cognitive impairment that precludes understanding of study procedures\n7. Participating in another clinical study and are at risk of an interaction between the study drugs\n8. Other conditions assessed by the investigators as inappropriate for participation in the study","18 Years",{"count":52,"type":20},30,"INTERVENTIONAL",[55],"PHASE4","Secukinumab is currently approved in Europe, US and China for the treatment of moderate to severe HS as a biologic agent targeting IL-17A.Two phase III clinical trials (SUNSHINE and SUNRISE) showed that 300 mg s.c. every 2 weeks resulted in 42% to 45% of patients achieving a clinical response (HiSCR) to HS, and the efficacy was sustained through 52 weeks.However, we found in clinical practice that some HS patients present with localized lesions (small areas of involvement, affecting only 1-2 anatomic areas) that are resistant to conventional therapy, and have not yet fulfilled surgical indications, and the need for systemic biologic therapy is controversial.Such patients often experience inadequate response or slow onset of action when they receive secukinumab by routine subcutaneous injection - possibly related to inadequate drug concentration in the focal lesional area and limited local anti-inflammatory effects after systemic administration.In addition, side effects of conventional subcutaneous injection system are greater, and the application is limited in some patients, so it is necessary to explore more appropriate and safer drug delivery method for localized skin lesions.Localized HS, local injection of lesions may enhance anti-inflammatory effects while reducing systemic exposure by increasing drug concentrations at the lesion site.Therefore, exploring novel modes of administration of secukinumab has practical clinical implications based on clinical practice needs and the context of the previous literature.In summary, by exploring the efficacy and safety of local skin injection of secukinumab, this study may provide a new strategy for the treatment of limited HS with sufficient scientific rationale and significant potential benefits and manageable risks.",[25,26,58],"Secukinumab","NOT_YET_RECRUITING","2025-12-02",{"date":62,"type":34},"2025-12-03",{"date":64,"type":20},"2025-12-01",{"date":66,"type":20},"2026-12-31",{"name":68,"class":41},"Peking Union Medical College",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":42},"100587269","efficacy-and-safety-of-secukinumab-in-conjunction-with-surgery-in-moderate-to-severe-hidradenitis-suppurativa-100587269","NCT06926192","Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa","Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: An Open-label Cohort Study in Real Clinical Practice","Inclusion Criteria:\n\n1. Patients aged 18 to 80 years old with moderate-severe (Hurley II-III) HS\n2. The diagnosis of HS was confirmed by histopathological examination in the Department of Pathology of our hospital\n3. Patients with HS who received secukinumab combined with surgery in the Department of Dermatologic Surgery of our hospital\n4. Patients with complete clinical data followed up for at least 1 year\n\nExclusion Criteria:\n\n1. Patients lost to follow-up\n2. Patients with less than one year of follow-up\n3. Patients who received additional adjuvant therapy during the follow-up period","80 Years",{"count":78,"type":20},100,"This study aims to retrospectively analyze the efficacy and safety of secukinumab combined with surgery in treating moderate to severe HS in real-world clinical practice, providing clinical practioners with real-world evidence in HS treatment.",[25,26,58],"2025-04-11",{"date":83,"type":34},"2025-04-16",{"date":85,"type":34},"2020-01-01",{"date":87,"type":20},"2025-06-21",{"name":68,"class":41},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":97,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":53,"phases":100,"briefSummary":102,"conditions":103,"keywords":104,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":42},"100572287","hs-abscesses-id-vs-punch-debridement-100572287","NCT06731309","HS ABSCESSES: I&D VS PUNCH DEBRIDEMENT","ABSCESS DRAINAGE in HIDRADENITIS SUPPURATIVA: INCISION and DRAINAGE VERSUS PUNCH DEBRIDEMENT","HSPUNCH","Inclusion Criteria:\n\n* Diagnosed with HS\n* Has an abscess requiring drainage with a maximum diameter of 5 centimeters.\n* Age 16 years or older\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Has other conditions that could interfere with the study, as estimated by physician\n* Unable to comply with follow-up visits\n* Allergic to lidocaine and\u002For adrenaline.","16 Years",{"count":99,"type":20},72,[101],"NA","This randomized-control trial is designed to determine the recurrence rate of HS abscesses following drainage via two methods: I\\&D with a linear incision and PD with an 8mm punch biopsy. In this context, recurrence is a newly described HS abscess adjacent to or within the previously operated area, for which a second intervention is deemed necessary. We hypothesize that PD may yield a more favorable recurrence rate. In addition to comparing recurrence rates, this randomized-control trial will also evaluate postprocedural pain, the occurrence and type of complications, and patients' quality of life associated with both procedures. These additional factors are crucial in assessing the overall effectiveness and patient satisfaction associated with each method, further informing the potential establishment of PD as the new gold standard for draining small, painful, acute HS abscesses.",[26],[105,106,107,108],"punch biopsy tool","drainage","abscess","I&D","2024-12-09",{"date":111,"type":34},"2024-12-12",{"date":113,"type":20},"2025-02",{"date":115,"type":20},"2027-04",{"name":117,"class":41},"Erasmus Medical Center"]